secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMNICELL, INC. (OMCL)
CIK:        0000926326
Form:       8-K
Filed at:   2026-07-30T10:34:15+00:00
Accession:  0000926326-26-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omnicell Q2 revenue $312M (+7% YoY); raises FY non-GAAP EPS and EBITDA guidance
-------------------------------------------------------------------------------

- GAAP net income $24M ($0.52 diluted EPS) vs $6M ($0.12) YoY; non-GAAP EPS $0.94 vs $0.45.
- Non-GAAP EBITDA $67M vs $38M YoY; received $15M in IEEPA tariff refunds.
- FY2026 guidance raised: non-GAAP EBITDA $175M-$185M, non-GAAP EPS $2.15-$2.30.
- Nnamdi Njoku promoted to President and COO effective July 1, 2026.
- Added Rick Couldry as SVP Chief Pharmacy & Clinical Officer and Dan Mandoli as SVP/GM Specialty Pharmacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926326/000092632626000019/0000926326-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926326/000092632626000019/omcl-20260730.htm
  HTML page:      https://secwatch.observer/filing/0000926326-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer